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Background: Non-invasive ventilation and exercise training might prove beneficial in the man-
agement of COPD patients.
Objetive: to compare the combined use of exercise training and non-invasive ventilation with
the two interventions separately in chronic respiratory failure due to chronic obstructive pul-
monary disease. As primary objective exercise capacity and secondary objectives gas ex-
change, peripheral muscle strength, BODE index, quality of life and systemic inflammatory
response.
Methods: Forty-five patients with severe chronic obstructive pulmonary disease were random-
ized into three groups for an intervention of 12 weeks: exercise training alone, ventilation
alone and combined treatment. We assessed exercise capacity, pulmonary function, BODE in-
dex, perception of dyspnoea, quality of life and several biomarkers.
Results: All exercise capacity parameters improved after training and the combined treat-
ment. In addition, peripheral muscle strength and six-minute walk distance increased after
ventilation. We found differences between the combined group and the ventilation group in
submaximal effort and in oxygen consumption. Changes in respiratory function were observed
in blood gases that improved after ventilation and the combined treatment, with differences
between these groups. BODE index, perception of dyspnoea and quality of life improved in all
three groups without differences between groups. Levels of interleukin 8 and tumour necrosisarmelo 90, 6A. 41011, Seville. Spain. Tel.: þ34 656486927.
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1742 E. Ma´rquez-Martı´n et al.factor a decreased after ventilation, and interleukin 8, C-reactive protein and surfactant pro-
tein D decreased after training, while all four of these markers fell after the combined treat-
ment. No differences between groups were found.
Conclusions: The combination of ventilation and exercise training had greater benefits than
the separate treatments: improvements were observed in both blood gases and the levels of
more biomarkers decreased. In addition, submaximal exercise capacity increased in all groups.
The improvements seen in BODE index, perception of dyspnoea and quality of life were similar
in all groups.
ª 2014 Elsevier Ltd. All rights reserved.Background
One type of treatment that is helpful for improving the
quality of life in COPD is pulmonary rehabilitation. In
addition to increasing exercise capacity, training improves
patient symptoms by relieving dyspnoea and reduces use of
health resources [1].
Studies evaluating theeffectiveness of homenon-invasive
ventilation (NIV) in long term in stable COPD patients have
produced variable results and controversial conclusions,
though there is evidence that selected patients may benefit
from this therapeutic approach [2]. In particular, NIV may
usefully contribute to improving muscle strength and
decreasing the number of hospital admissions, and conse-
quently improve quality of life in these patients [3].
It seems reasonable that the combination of the two
therapeutic approaches, NIV and exercise training might
prove beneficial in the management of these patients.
Some studies have made a partial evaluation of the com-
bined use of these treatments with small numbers of pa-
tients [4e7]. However, only two types of groups have been
evaluated: patients undergoing training and patients
receiving both training and ventilation (that is, no com-
parison has been made to a group receiving ventilation
only).
Given this, we believed it would be interesting to design
an exercise training programme for COPD patients com-
bined with ventilatory support at night, and explore
whether there were benefits compared to the use of each
treatment in isolation.
Accordingly, the primary objective of this study was to
test whether there was a beneficial effect on exercise ca-
pacity as time in submaximal exercise test from training
combined with NIV, compared to each of the treatments
alone in patients with COPD. As secondary objectives, we
compared the impact of combined treatment on gas ex-
change, peripheral muscle strength, BODE index, quality of
life and systemic inflammatory response.Methods
Study participants
This was an interventional study in which 45 patients were
prospectively recruited from May 2007 to September 2011
and randomized via a computer-generated randomisationsequence into one of three groups of 15 patients: ventila-
tion group, training group, and training and ventilation
group. Inclusion criteria were: being an adult patient with a
diagnosis of COPD, as defined by the GOLD criteria [8];
having been clinically stable for at least the previous three
months; airflow obstruction with forced expiratory volume
in the first second of expiration (FEV1) <50%; and chronic
respiratory failure with hypoxaemia (arterial oxygen pres-
sure, PaO2 < 60 mmHg) and hypercapnia (arterial carbon
dioxide pressure, PaCO2 > 45 mmHg). According to the
GOLD guideline available at the moment of the trial, pa-
tients under this condition were classified into GOLD stage
4. These are the actual indications for home mechanical
ventilation in COPD [9]. Patients selected for NIV were
those randomized to receive it. Our Clinical Research Ethics
Committee approved the study protocol, and the study was
registered on ClinicalTrials.gov (ID NCT01377818). Written
informed consent was obtained from subjects prior to their
inclusion.
All patients were receiving adequate treatment for their
disease including inhaled medications (basically long-acting
muscarinic antagonist and the combination of a long-acting
beta2 agonist with an inhaled corticosteroid) and long-term
oxygen therapy according to current indications [10].
Additional details of the methods are provided in the
Online Supporting Information.
Training programme
Training sessions were carried out on three non-consecutive
days every week for 12 weeks. The programme was struc-
tured as reported previously [11], and consisted of a com-
bination of resistance and strength training [12e14].
Ventilation programme
NIV was administered using a bilevel positive airway pres-
sure system administered by a nasal mask (Respironics).
The system was initially programmed to provide: 10 cmH2O
inspiratory positive airway pressure (IPAP), and 4 cmH2O
expiratory positive airway pressure (EPAP), using the ST
mode. The IPAP was increased progressively to a maximum
of 20 cmH2O, depending on patient tolerance, clinical
response and arterial oxygen saturation (as assessed by
continuous pulseoximetry).
Patients received continuous ventilatory support during
the night hours (for 6e8 h per night).
Non-invasive ventilation and exercise training in COPD 1743Combined programme
This group received both of the aforementioned treat-
ments, that is ventilation during sleep hours and training
for a 12 week period.Measurements
The following data were collected for the 43 patients who
completed the study. Maximal cardiopulmonary exercise
testing was performed on a cycle ergometer [14,15]. Spe-
cifically, the submaximal endurance test was conducted
with cycle ergometer at 70% of the peak work rate ofFigure 1 Consortreached in the maximal cardiopulmonary exercise test [16].
Peripheral muscle strength was assessed using the one
repetition maximum test, while Six-minute walk distance
(6MWD) and BODE index were also measured [17]. We
performed pulmonary function tests including spirometry
[18], and measured arterial blood gases [19]. Dyspnoea was
assessed using the modified Medical Research Council
(mMRC) dyspnoea scale [20e22] and quality of life using the
Chronic Respiratory Disease Questionnaire (CRDQ) [23,24].
We evaluated several biomarkers namely C-reactive protein
(CRP), tumour necrosis factor a (TNF-a), interleukin 6 and 8
(IL-6, IL-8) and surfactant protein-D (SP-D) in serum sam-
ples by ELISA technique called Human cytokine Array 1
(SearchLight ).flow diagram.
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Statistical analysis was performed using IBM SPSS Statistics
(Version 19.0 for Windows; SPSS Inc., Chicago Illinois).
The sample size was calculated for the hypothesis that a
training programme combined with NIV treatment would
significantly increase exercise capacity compared to each
treatment alone and based on the workload increase in the
cardiopulmonary exercise test in a prior study [9]. Ac-
cording to an improvement in submaximal exercise capacity
(in minutes) greater than 20% in the exercise test, with a
standard deviation of 10 min, a level of 0.05, b level of
0.20 (two-tailed test procedures), and assuming a loss
percentage of 15%, 15 patients per each group was
calculated.
Many variables were found to have a non-normal distri-
bution and accordingly we calculated medians, inter-
quartile ranges and minima and maxima, and these are
reported as: median [25th percentile 75th percentile].
The comparison of before and after the response to the
intervention in each test was performed using paired or
repeatedmeasures Student’s t-tests when the data followed
a normal distribution, and otherwise the Wilcoxon test.
Comparisons between groups were performed using
analysis of variance (ANOVA) or the Welch test where
appropriate, and for data that did not follow a normal
distribution, we applied the KruskaleWallis test and the
Mann Whitney U test using the Bonferroni correction.
Differences were considered significant for p < 0.05
when parametric techniques were applied, and p < 0.0167Table 1 Main data at baseline (before the interventions).
Whole sample (median [IQ]) NIV
FVC% 74 [62e85] 7
FEV1 % 34 [29e43] 3
TLC (%) 106 [98e120] 11
VR (%) 159 [140e187] 16
KCO (%) 75 [53e97] 7
IC (%) 69 [50e76] 6
PaO2 (mmHg) 54 [51e57] 5
PaCO2 (mmHg) 50 [48e53] 5
1RM chest pull (kg) 30 [24e36] 2
1RM leg extension (kg) 24 [18e32] 2
Power % 35 [27e47] 3
VO2% 55 [46e67] 6
6MWD (m) 343 [280e444] 35
Endurance (minutes) 10.25 [6.09e19.21]
BODE index 5 [4e6]
MRC score 3 [2e3]
Total CRDQ score 4.34 [3.82e4.93]
CRP (mg/l) 10.8 [5.2e24] 1
TNF-a (pg/ml) 1.81 [1.16e3.35]
IL-6 (pg/ml) 4.79 [2.78e9.23]
IL-8 (pg/ml) 3.31 [2.2e4.95]
SP-D (ng/ml) 160.57 [110e216] 13
IQ: interquartile range; NIV: non-invasive ventilation group; ET: ex
expiratory volume in first second; TLC: total lung capacity; RV: reser
ratory capacity; PaO2: arterial oxygen pressure; PaCO2: arterial carb
consumption; 6MWD: 6 min walk distance; mMRC: modified Medical Re
CRP: C-reactive protein; TNF-a: tumour necrosis factor- a; IL-6: interfor multiple comparisons, when nonparametric techniques
were used.Results
Forty five of the sixty patients assessed for eligibility were
enrolled. Two of the patients who started the study with-
drew due to exacerbations of their underlying disease
(COPD) that made them miss five or more training sessions.
Accordingly, the analysis was based on 15 patients in the
ventilation group, 14 patients in the training group and 14
patients in the combined intervention group (Fig. 1, Con-
sort Flow Diagram). All patients were caucasian, without
comorbidities that prevent to participate in the study and
were under correct treatment. Oxygen therapy was used if
the patient had indication (PaO2 < 55 mmHg): 10 patients in
the ventilation group, 9 in the training group and 8 patients
in the combined group.
The male to female ratio was 41:2 and the median age
69 [64e73] years. Patients who received NIV used the de-
vice for 7 [6.5e9] hours per night. The pressures used were
a median of expiratory positive airway pressure of 4 cm H2O
and an inspiratory positive airway pressure of 16 cm H2O.
Table 1 lists the main data for all participants at base-
line, that is, before the interventions. There were no sig-
nificant differences between the groups.
Further details are provided on these baseline data and
all the following results in the Online Supporting
Information.(median) ET (median) NIV-ET (median) p
3 76 71 0.87
5 39 28 0.4
0 120 103 0.2
6 164 151 0.8
7 61 82 0.4
7 70 67 0.6
2 54 56 0.1
1 48 50 0.11
0 19 20 0.6
6 23 29 0.4
5 36 33 0.9
0 56 54 0.5
0 361 329 0.2
6.4 15.7 9.7 0.06
5 5 5 0.2
3 3 3 0.6
4.1 4.8 4.1 0.1
0.8 10.6 13.8 0.3
1.8 1.8 1.9 0.8
4.2 4.7 6.8 0.5
2.2 3.3 3.1 0.07
1 174 192 0.5
ercise training group; FVC: forced vital capacity; FEV1: forced
ve volume; KCO: carbon monoxide transfer coefficient; IC: inspi-
on dioxide pressure; 1RM: 1 repetition maximum; VO2%: oxygen
search Council; CRDQ: Chronic Respiratory Disease Questionnaire;
leukin 6; and SP-D: surfactant protein D.
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Exercise capacity improved in the rehabilitation and the
combined group as showed in Fig. 2 but not in the venti-
lation group. Comparing the groups, we found differences
between the combined group and the ventilation group in
submaximal effort (Fig. 2).
Secondary objective
Exercise parameters
Patients who received ventilation showed improvement in
upper and lower limbs in the one repetition maximum test
as a measure of peripheral muscle strength (Fig. 3) and the
6MWD increased by 40 m (pZ 0.012) (Fig. 4). On the other
hand, patients who underwent training, as expected,
improved in: peripheral muscle strength, with increases in
the weights used on most of the exercises (Fig. 3) and ex-
ercise capacity (42 m, pZ 0.012, in 6MWD). The combined
group improved in absolutely all the exercise parameters:
peripheral muscle strength (Fig. 3), 6MWD, which increased
by 83 m (p < 0.001) (Fig. 4) as well as in exercise capacity
(Fig. 2). Comparing the groups, we found differences be-
tween the combined group and the ventilation group in
oxygen consumption, as can be seen in Fig. 2.Figure 2 Differences in oxygen consumption and endurance (maPulmonary function parameters
Blood gas parameters improved in the ventilation group
(PaCO2 decreasing from 51 to 47 mmHg, p Z 0.008) and in
the combined intervention group (PaO2 increasing from
56 mmHg to 59.5 mmHg, p Z 0.02; and PaCO2 decreasing
from 50 mmHg to 45 mmHg, p < 0.001) (Fig. 5). There were
no changes in blood gas parameters in the training group.
Comparing the groups, no significant differences were
detected before the intervention and after the intervention
differences were only found in PaO2, these being between
the combined group and the group receiving ventilation
(Fig. 5).
BODE, dyspnoea and quality of life parameters
Table 2 shows the data before and after each intervention.
The BODE index, dyspnoea and all four components of
quality of life considered significantly improved in all three
groups of patients (Fig. 6). No significant differences were
found between groups.
Biomarkers parameters
In Table 3 we report data on the levels of biomarkers. NIV
reduced levels of TNF-a and IL-8, while training reduced
levels of CRP, IL-8 and SP-D. Consistent with this, the levels
of PCR, TNF-a, IL-8 and SP-D were all lower after theximal and submaximal exercise test) data in the three groups.
Figure 3 Differences in peripheral muscle strength (1 repetition maximal test) of upper and lower limb data in the three groups.
1746 E. Ma´rquez-Martı´n et al.combined intervention. Comparing groups, we did not find
any significant differences. Any relationship was found
between functional parameters and serum parameters.Discussion
Submaximal exercise capacity increased in the three groups
studied: NIV, exercise training and the combination of both,
without differences between them. The combined used of
NIV and exercise training was found to provide greater
benefits than each of the two treatments separately in
blood gases (both O2 and CO2) and the level of more bio-
markers decreased. Further, improvements in BODE index,
dyspnoea and quality of life were similar with ventilation,
training or the combination of treatments. This is the first
study jointly comparing the effects of three groups of pa-
tients receiving these two treatments. Additionally, we
provide data on the changes of the systemic inflammatoryload in response to either treatment. To conduct the study
we studied patients who were eligible to use any of the two
therapies, so the results are applicable the use of both in
the real life. The fact that the message is in the line of
current knowledge strengthens our results and adds new
information to the field.
Chronic respiratory fatigue has been described in COPD
in relation with severe lung function impairment [25]. That
could contribute to the decrease in exercise tolerance
found in these patients. For this reason, it is seems plau-
sible that the muscle rest due to ventilation would improve
peripheral muscle strength and exercise tolerance. We are
not, however, aware of any research demonstrating
improved respiratory or peripheral muscle strength, with
the exception of one recent study that explored the use of
ventilation during exercise [26]. Our study is the first to
demonstrate an improvement in peripheral muscle strength
with the use of night ventilation alone in patients with
COPD. In such patients, it has been observed that the
Figure 4 Differences in six minutes walking test data in the
three groups.
Table 2 BODE, dyspnoea and quality of life data before and af
Pre
Med. IQR Min-Max
HMV BODE 5 [3e6] (3e7)
MRC 3 [2e3] (1e4)
CRDQ total 4.1 [3.76e4.67] (2.83e6.14)
ET BODE 5 [4e6] (3e6)
MRC 3 [2e3] (2e3)
CRDQ total 4.78 [4.13e5.32] (3.35e5.75)
HMV-ET BODE 5 [4.75e6.25] (4e8)
MRC 3 [2e3] (2e4)
CRDQ total 4.12 [3.82e4.73] (3.68e5.13)
Med: medium; Min: minimum; Max: maximum; IQR: interquartile ra
Respiratory Disease Questionnaire; HMV: home mechanical ventilatio
p1: differences between pre and post; p2: differences between group
Bold represents statistically significant.
Figure 5 Differences in gas exchange paramet
Non-invasive ventilation and exercise training in COPD 1747decrease in diaphragmatic activity by ventilation is asso-
ciated with increased inspiratory pressure [27], an increase
in muscle strength and increased resistance of the respi-
ratory muscles during the day [28]. This improvement in
peripheral muscle strength in turn seems to improve sub-
maximal exercise capacity, as seen by the improvement in
6MWD in our patients and has been demonstrated by other
authors [27,29].
The combination of ventilation and pulmonary rehabili-
tation have previously been found to improve endurance
[4], distance walked in the shuttle walk test [5] and the
6MWD [7,30]. In our study group, no statistically significant
differences were found in the 6MWD between groups, but it
is noteworthy that the group receiving both ventilation and
training had a median improvement of 83 m versus 40 m in
the group receiving ventilation and 42 m in the group that
underwent training.
The use of NIV has been demonstrated to improve pul-
monary function parameters, especially with respect to
blood gases [31,32]. The indication to receive home NIV has
been controversial during the last decades and still is. The
latest Cochrane review found that nocturnal-NIV at home in
hypercapnic patients with stable COPD had no consistentter each intervention.
Post p1 p2
Med. IQR Min-Max
3 [2e4] (1e5) 0.001 0.5
1 [1e2] (0e3) 0.002 0.6
4.6 [4.06e5.21] (3.88e6.33) 0.008 0.06
3 [2e4.25] (2e5) 0.003 0.5
1.5 [1e2] (0e2) 0.002 0.6
5.61 [5.04e5.79] (3.89e6.4) 0.005 0.06
3.5 [2e4.25] (1e6) 0.001 0.5
1 [1e2] (0e2) 0.001 0.6
5.26 [4.54e5.57] (3.99e6.02) 0.001 0.06
nge; mMRC: modified Medical Research Council; CRDQ: Chronic
n; and ET: exercise training.
s post-intervention.
ers (pO2 and PCO2) data in the three groups.
Figure 6 Differences in quality of life data (Chronic Respiratory Disease Questionnaire) in the three groups.
Table 3 Biomarkers parameters before and after each intervention.
Pre Post p1 p2
Med. IQR Min-Max Med. IQR Min-Max
HMV CRP (mg/l) 10.8 [5.2e16] (1.9e26) 7 [4.7e13] (1.1e15.9) 0.095 0.71
TNF-a (pg/ml) 1.81 [1.5e3.57] (0.02e6.7) 0.94 [0.07e1.81] (0.01e6.76) 0.047 0.23
IL-6 (pg/ml) 4.2 [2.42e9.9] (0.01e16.6) 2.96 [2.15e4.65] (1.19e8.34) 0.156 0.58
IL-8 (pg/ml) 2.2 [0.03e3.77] (0.01e4.11) 0.6 [0.01e2.2] (0.01e4.56) 0.047 0.71
SP-D (ng/ml) 130.9 [76.6e230.3] (7.66e370) 77.5 [59e159] (46e208) 0.083 0.16
ET CRP (mg/l) 10.6 [3.92e18.1] (1.2e30) 7.3 [3.12e12.5] (1.3e21) 0.011 0.71
TNF-a (pg/ml) 1.81 [0.47e3.35] (0.08e6.26) 1.31 [0.55e2.41] (0.29e4.71) 0.638 0.23
IL-6 (pg/ml) 4.74 [3.27e6.82] (1.54e14.78) 3.38 [2.33e5.67] (0.53e11.18) 0.272 0.58
IL-8 (pg/ml) 3.31 [2.87e5.13] (1.41e7.27) 2.58 [1.41e4.15] (1.27e6.48) 0.041 0.71
SP-D (ng/ml) 173.6 [116e221] (68.56e326.5) 143 [99e175] (69.7e264) 0.027 0.16
HMV-ET CRP (mg/l) 13.8 [6.02e44.4] (1.5e7.4) 7.3 [4.85e19.25] (2e35) 0.016 0.71
TNF-a (pg/ml) 1.92 [1.05e4.33] (0.08e7.38) 1.05 [0.56e2.69] (0.08e4.02) 0.047 0.23
IL-6 (pg/ml) 6.84 [2.69e9.32] (1.45e14.66) 3.75 [2.65e5.69] (1.37e12.95) 0.064 0.58
IL-8 (pg/ml) 5.12 [3.75e6.79] (0.62e8.49) 2.73 [1.43e4.24] (0.14e7.27) 0.002 0.71
SP-D (ng/ml) 192 [134e220] (57.9e288) 130 [103e150] (68.7e195) <0.001 0.16
Med: medium; Min: minimum; Max: maximum; IQR: interquartile range; CRP: C-reactive protein; TNF-a: tumour necrosis factor- a; IL-6:
interleukin 6; SP-D: surfactant protein D; HMV: home mechanical ventilation; and ET: exercise training.
p1: differences between pre and post; p2: differences between groups post-intervention.
Bold represents statistically significant.
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Non-invasive ventilation and exercise training in COPD 1749clinically or statistically significant effect on gas exchange,
exercise tolerance, HRQoL, lung function, respiratory
muscle strength or sleep efficiency [2]. However, a recent
study has found that the addition of long-term NIV to
standard treatment improves survival of patients with hy-
percapnic, stable COPD when NIV is targeted to greatly
reduce hypercapnia [33]. On the other hand, exercise
training did not improve pulmonary function, as we knew
[34]. Interestingly, the combined use of the two treatments
enhanced gas exchange compared to ventilation in isola-
tion, levels of PaO2 rising and PaCO2 decreasing. In spite of
a good patient compliance with ventilator therapy, they
only improved their blood gases with 3e5 mmHg, which
could be a rather low figure. We could attribute that to
ineffectively low ventilator pressures and could expect that
higher pressures could reach better benefits.
The combination of training with ventilation may allow
respiratory muscles to rest, increasing alveolar ventilation,
decreasing hypoventilation and resensitizing the respiratory
centres. The correction of hypercapnia during the hours of
NIV seems to allow the recovery of the sensitivity of the
respiratory centres, so they are then able to maintain
adequate levels of minute ventilation throughout the day,
reducing daytime hypercapnia and improving oxygenation.
Our study is the first to evaluate the benefits in terms of
BODE index after a programme of ventilation. The BODE
index improved in the group that received exercise training
alone, consistent with results reported by Cote et al. [35].
As previous studies that have analysed the two in-
terventions jointly have not assessed the BODE index, our
work is the first confirm the benefits of combination of the
two therapies with respect to this parameter.
Most studies that have considered NIV or pulmonary
rehabilitation separately have shown improvement in
perception of dyspnoea and/or quality of life
[27,31,32,36e38]. Further, previous studies that have
analysed ventilation added to respiratory rehabilitation
have demonstrated the same benefits in perception of
dyspnoea and quality of life as our study [4e7]. On the
other hand, comparing the groups, we did not find any
significant differences in these parameters between the
combined group and the use of each intervention in isola-
tion. This contrasts with the results of some previous
studies which found differences between combined treat-
ment and pulmonary rehabilitation/physical training only
groups in total CRDQ score and magnitude of fatigue [5,6],
though analysis two years after treatment found no dif-
ferences in either the mMRC or CRDQ score between a
trained group and a group that had received training and
NIV [30]. Once again, we have found no studies comparing a
combined intervention group with a ventilation-alone
group.
It seems to be important to identify a biomarker that
accurately represents the natural course of COPD, improve
risk stratification and assesses the impact of treatments on
candidate markers [39,40]. Our study is one of the first
analysing the effect of NIV on these biomarkers. TNF-a has
been implicated as an inflammatory mediator in diseases
such as cancer, heart failure and cystic fibrosis. Serum TNF-
a levels have also been studied in COPD patients, and were
seen to rise in a similar way to IL-8 levels [41]. These two
molecules are part of the inflammatory cascade, andaccordingly the decrease in their levels seen with NIV could
indicate that one beneficial effect of this treatment in
COPD patients is a decrease in inflammation This is a novel
message that completes current knowledge on the disease
and the response to treatments. Additionally, we have not
found any relationship between functional parameters and
serum parameters. This could be due to the non-
improvement of functional parameters as shown in the
Online Supporting Information. Consequently the improve-
ment shown in the development of some of the serum pa-
rameters is not related to the lack of improvement in
functional parameters. Interestingly, a recent publication
has found an increase in the systemic inflammation as a
consequence of NIV [42]. However this was an observational
cohort study. The lack of randomization remains a key flaw
of this work.
The beneficial effect that the exercise training may
exert on biomarkers is not yet clear. Several studies have
measured changes over time in inflammatory markers, such
as TNF-a, CRP and IL-6, after the completion of a pulmo-
nary rehabilitation programme in COPD patients, and no
beneficial results have been demonstrated [43e45]. In our
study, we observed a decrease after training in levels of
both CRP and IL-8 (the latter also seen after ventilation),
and we believe that these reflect the benefit of the exer-
cise. On the other hand, a reduction in levels of SP-D after
the completion of exercise has been demonstrated in
healthy subjects [46], and anti-inflammatory therapies
used in COPD, namely corticosteroids, have also been found
to reduce levels of SP-D [47]. The decrease in the levels of
this biomarker seen in our patients together with the
aforementioned findings by other authors support the the-
ory of systemic improvement brought about by the exercise
training, elevated levels of SP-D being associated with
poorer lung function and quality of life [48].
Studies that have combined with the exercise training
and NIV have not measured biomarkers as an indicator of
response to the two interventions together. We observed
decreases in the levels of CRP and SP-D, also observed when
exercise training was given in isolation; TNF-a, also seen
when patients only received ventilation; and IL-8, also
observed with each of the interventions alone. That is,
overall, the combined use of NIV and training lead to im-
provements in more biomarkers than when these treat-
ments were given in isolation.
The principal limitation of our study is that was not
blinded or placebo-controlled, that is, we did not use a
device similar to the NIV to serve as a placebo. We note
that this is difficult to do and similar studies share this
weakness [5e7]. However, even with this sham ventilation
the study would still be unblinded, since there sham reha-
bilitation programs are not available. Other limitation is the
lack of power of all variables assessed, as the study was
only powered for the primary outcome, time in submaximal
exercise, which made the sample size calculation probably
too optimistic. We note again the low ventilator pressures
used, which could make expect that higher pressures could
reach better benefits.
In summary, we can conclude that submaximal exercise
capacity increased in the three groups studied, NIV, exer-
cise training and the combination of both without differ-
ences between them and the combined use of NIV and
1750 E. Ma´rquez-Martı´n et al.exercise training could provide greater benefits than ach-
ieved with each of the two therapies separately: gas ex-
change is enhanced (as reflected in both arterial oxygen
and carbon dioxide pressures) and the levels of more bio-
markers decrease.
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